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($US27,682). CONCLUSION: As far as effectiveness, ambula-
tory care are the same. Self-injection therapy is preferable, espe-
cially including indirect costs.
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Rheumatoid arthritis (RA) is an autoimmune disease with an
unknown etiology that results in over 9 million physician visits
and more than 250,000 hospitalizations per year. TNF-alpha
inhibitors are effective agents in treating RA. However, their
cost-effectiveness as ﬁrst-line agents has not been investigated.
OBJECTIVE: To examine the cost-effectiveness of using TNF-
alpha inhibitors as ﬁrst-line agents in rheumatoid arthritis from
a societal perspective, and secondly determine which of the
current TNF-alpha inhibitors is the most cost-effective in this
role. METHODS: A Markov model was developed utilizing a
discount rate of 3% and a lifetime time horizon for a hypothet-
ical cohort of United States females aged 55–60 who are diag-
nosed with RA. The source of data for predicted probabilities,
expected mortality rates, and treatment costs in year 2003
dollars (drug, toxicity, monitoring, and hospitalization) is from
the literature. These costs are assigned in ﬁve-year cycles along
with the effect on quality adjusted life years (QALY), which is a
function of the Health Assessment Questionnaire score. A sen-
sitivity analysis was conducted on all relevant parameters.
RESULTS: Etanercept was the most cost-effective TNF-alpha
inhibitor. It had an incremental cost-effectiveness ratio (ICER) of
$80,350 versus standard therapy. When taking into considera-
tion age of diagnosis and potential reduction in compliance-
related efﬁcacy with traditional DMARDS, the ICER varies from
$56,412 to $86,211. When assigned etanercept’s ﬁrst-line efﬁ-
cacy in the sensitivity analysis, adalimumab (ADAL) and inﬂix-
imab (INF) had ICERs of $82,783 and $65,881 versus standard
therapy, respectively. CONCLUSION: Depending where the
cost-effective threshold is drawn ($50,000–$100,000), etaner-
cept is relatively cost-effective versus standard care at $80,350.
ADAL and INF may also be cost-effective depending on results
of future head-to-head monotherapy trials.
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OBJECTIVE: Adalimumab is a new human TNF-antagonist
monoclonal antibody used to treat patients with moderate to
severe RA. We used an economic model to compare its cost effec-
tiveness to other biologic disease modifying anti-rheumatic drugs
(DMARDs) such as etanercept and inﬂiximab. METHODS:
Adhering to the US cost-effectiveness panel and AMCP guidance,
the model evaluated adalimumab with methotrexate (MTX) as
it would be given in typical practice. The analysis was performed
over 3 years from a payor’s perspective and is based on individ-
ual simulation of 10,000 RA patients. Patients’ clinical responses
were evaluated every six months. Probabilities were derived from
clinical (Phase III ARMADA trial) and long-term observational
databases. Costs included the drug, monitoring, administration,
RA-related hospitalization and treatment of adverse events.
Comprehensive sensitivity analyses were performed to highlight
key uncertainties. RESULTS: Using ACR50 clinical response
data, adalimumab + MTX resulted in a more sustained response
with a lower cost-effectiveness ratio compared to etanercept +
MTX and with inﬂiximab + MTX. Adalimumab data entered
into the 3-year model yielded ﬁndings that patients had 
1.36 years of good clinical response and a cost-effectiveness 
ratio of $45,600 per year of response. Results for etanercept 
+ MTX were 1.16 years and $53,900, while results for inﬂix-
imab + MTX were 0.69 years and $95,600. Sensitivity analysis
on clinical response conﬁdence intervals (CIs) revealed that cost-
effectiveness of the biologics overlapped, however CIs for adal-
imumab were narrower because of larger trial sample sizes.
CONCLUSION: Uncertainty in comparative efﬁcacy is currently
too large to deﬁnitively prove that one biologic DMARD is
always more cost-effective than the others, but larger sample
sizes in adalimumab trials give higher certainty regarding its efﬁ-
cacy. Since formulary decisions are made on data currently avail-
able, these results suggest that adalimumab + MTX is as cost
effective and possibly more cost effective than the other biologic
DMARDs.
PAR6
COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR
RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE
RESPONSE TO METHOTREXATE
Patel VD, Hay J
University of Southern California, Los Angeles, CA, USA
BACKGROUND: Several treatment options are now available
for rheumatoid arthritis patients that have inadequate response
to methotrexate alone. These agents are different in terms of
their efﬁcacy, safety, cost, and ease of administration. This 
makes it essential to perform a cost-effectiveness analysis taking
into account the important clinical and cost differences. This
model focuses on two combinations with proven efﬁcacy, in 
adequate well controlled trials, for patients with inadequate
response to methotrexate. OBJECTIVE: Compare 2-year cost-
effectiveness of two different treatment strategies, from the 
societal perspective, for rheumatoid arthritis patients with inad-
equate response to methotrexate: 1) Start patients on methotrex-
ate (MTX) + leﬂunomide (LEF), 2) Start patients on MTX +
tumor necrosis factor a (TNF-a). METHODS: A 2-year decision
analysis model with four semiannual cycles was developed to
estimate the average cost/QALY, and the incremental cost-effec-
tiveness ratio (ICER) for the two options, for female patients
with mean age of 50 years. The model input parameters such as;
response rates, dropout rates, costs, and QoL values were
obtained either from published literature, or from expert
opinion. Univariate sensitivity analysis was conducted to esti-
mate percent changes in ICER from the base case analysis with
change in gender, age, response rates, drug costs, and other para-
meters. RESULTS: The 2-year base case average cost/QALY is
$8,551 for patients started on MTX + LEF, and $19,340 for
patients started on MTX + TNF-a. The base case ICER for MTX
+ TNF-a is $36,147. In the univariate sensitivity analysis, ICERs
varied from $25,267 to $63,479. The model was extremely sen-
sitive to change in drug costs, and to the method used for con-
version of HAQ/QoL scores into QALYs. CONCLUSION: This
2-year cost-effectiveness model suggests that for patients with
inadequate response to methotrexate alone, the combination 
of MTX + TNF-a is a cost-effective strategy compared to MTX
+ LEF.
